Trabectedin Is Active against Two Novel, Patient-Derived Solitary Fibrous Pleural Tumor Cell Lines and Synergizes with Ponatinib

Trabectedin Is Active against Two Novel, Patient-Derived Solitary Fibrous Pleural Tumor Cell Lines and Synergizes with Ponatinib

Solitary fibrous tumor of the pleura (SFT) is a rare disease. Besides surgery combined with radiotherapy in nondisseminated stages, curative options are currently absent. Out of fourteen primo-cell cultures, established from surgical SFT specimens, two showed stable in vitro growth. Both cell models...

Full description

Bibliographic Details
Main Authors: Bahil Ghanim, Dina Baier, Christine Pirker, Leonhard Müllauer, Katharina Sinn, Gyoergy Lang, Konrad Hoetzenecker, Walter Berger
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cancers
Subjects:
solitary fibrous tumor
<i>NAB2-STAT6</i> gene fusion
targeted therapy
trabectedin
ponatinib
dasatinib
Online Access:https://www.mdpi.com/2072-6694/14/22/5602

Internet

https://www.mdpi.com/2072-6694/14/22/5602

Similar Items